A phase III, flexible dose titration followed by a randomized double-blind study of controlled release OROS hydromorphone hydrochloride compared to placebo in patients with chronic OA pain.

Trial Profile

A phase III, flexible dose titration followed by a randomized double-blind study of controlled release OROS hydromorphone hydrochloride compared to placebo in patients with chronic OA pain.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 May 2012

At a glance

  • Drugs Hydromorphone (Primary)
  • Indications Musculoskeletal pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Neuromed Pharmaceuticals
  • Most Recent Events

    • 19 May 2012 Results presented at the 31st Annual Scientific Meeting of the American Pain Society.
    • 20 Mar 2012 Company (Mallinckrodt) added and actual patient number is 200 as reported by ClinicalTrials.gov.
    • 09 Dec 2008 Status changed from recruiting to completed, based on information from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top